Pages that link to "Q33688639"

The following pages link to Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids (Q33688639):

Displaying 20 items.

• Postprandial Metabolism of Macronutrients and Cardiometabolic Risk: Recent Developments, Emerging Concepts, and Future Directions. (Q30362026) (← links)
• Pediatric Metabolic Syndrome: Pathophysiology and Laboratory Assessment (Q33551642) (← links)
• Role of the Enterocyte in Fructose-Induced Hypertriglyceridaemia (Q33616687) (← links)
• Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans (Q33789371) (← links)
• Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans (Q34526962) (← links)
• Glucagon-like peptide-2 regulates release of chylomicrons from the intestine. (Q35046115) (← links)
• Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. (Q35186665) (← links)
• The Regulation of Lipid Deposition by Insulin in Goose Liver Cells Is Mediated by the PI3K-AKT-mTOR Signaling Pathway (Q35623077) (← links)
• Deregulated Lipid Sensing by Intestinal CD36 in Diet-Induced Hyperinsulinemic Obese Mouse Model (Q35883898) (← links)
• Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol (Q37333546) (← links)
• Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance. (Q37590276) (← links)
• Gut-liver interaction in triglyceride-rich lipoprotein metabolism (Q37892758) (← links)
• Short Term Palmitate Supply Impairs Intestinal Insulin Signaling via Ceramide Production (Q42395469) (← links)
• Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment (Q42635500) (← links)
• A novel method for measuring intestinal and hepatic triacylglycerol kinetics (Q44426071) (← links)
• Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. (Q49926115) (← links)
• Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study (Q50976554) (← links)
• Risk prediction with triglycerides in patients with stable coronary disease on statin treatment (Q51319217) (← links)
• Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. (Q51381989) (← links)
• Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes. (Q55001495) (← links)